

# Idris Boudhabhay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6245368/publications.pdf>

Version: 2024-02-01

16  
papers

671  
citations

1163117

8  
h-index

996975

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1360  
citing authors

#	ARTICLE	IF	CITATIONS
1	Authors' Reply. Journal of the American Society of Nephrology: JASN, 2022, 33, 458-459.	6.1	1
2	COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrology Dialysis Transplantation, 2022, 37, 1357-1365.	0.7	17
3	Presentation and outcomes of SARS-CoV-2 Omicron variant infection in haemodialysis patients. CKJ: Clinical Kidney Journal, 2022, 15, 1785-1788.	2.9	1
4	Hepato-splenic abscesses in a sickle cell disease patient. American Journal of Hematology, 2022, 97, 1118-1119.	4.1	0
5	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	7.1	110
6	Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. Kidney International, 2021, 99, 581-597.	5.2	48
7	Reappraisal of Renal Arteritis in ANCA-associated Vasculitis: Clinical Characteristics, Pathology, and Outcome. Journal of the American Society of Nephrology: JASN, 2021, 32, 2362-2374.	6.1	24
8	Impact of pre-eclampsia on renal outcome in sickle cell disease patients. British Journal of Haematology, 2021, 194, 1053-1062.	2.5	4
9	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	11.9	357
10	Complement factor H: a guardian within?. Kidney International, 2021, 100, 747-749.	5.2	2
11	Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis. Frontiers in Immunology, 2020, 11, 1772.	4.8	8
12	Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. American Journal of Hematology, 2020, 95, 456-464.	4.1	46
13	Atypical hemolytic uremic syndrome and hypertensive crisis. Kidney International, 2019, 96, 1239.	5.2	2
14	Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency. Kidney International Reports, 2019, 4, 1354-1358.	0.8	3
15	Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme. Molecular Immunology, 2019, 111, 205-208.	2.2	8
16	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica, 2019, 104, 2501-2511.	3.5	40